Description

Technical Parameters

Introduction

raws

product-1400-1400

Products Description

### Systematic Analysis of Vardenafil Raws Powder

Vardenafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor, mainly used to treat male erectile dysfunction (ED). As the core ingredient of raw materials, its powder form plays an important role in the pharmaceutical industry. This article will systematically analyze Vardenafil Raws Powder from the aspects of chemical properties, classification, production process, quality standards, application fields and market prospects.

#### 1. Chemical properties and structure

**Chemical name**:

2-[(1-ethyl-3-(4-ethoxyphenyl)-7-methyl-4-oxo-3,4-dihydropyrazolo[4,3-d]pyrimidin-5-yl)sulfonyl]-4-methylpiperazine-1-carboxylic acid ethyl ester

**Molecular formula**: C₂₃H₃₂N₆O₄S

**Molecular weight**: 488.6 g/mol

**CAS number**: 224785-90-4

**Appearance**: White to off-white crystalline powder

**Solubility**: Slightly soluble in water, easily soluble in organic solvents (such as DMSO, ethanol).

**Structural features**:

Vardenafil molecule contains a pyrazolopyrimidinone core structure and has a high affinity PDE5 binding site. Its sulfonyl and piperazine rings enhance the selectivity and metabolic stability of the drug, reduce cross-reactions with other PDE subtypes (such as PDE6), and thus reduce the risk of visual side effects.

#### 2. Classification and characteristics of vardenafil API

According to differences in synthesis process, purity grade and use, vardenafil API powder can be divided into the following categories:

##### 1. **Standard Grade API**

- **Purity**: ≥98%

- **Advantages**:

- Cost-effective, suitable for large-scale preparation production;

- Meet the basic standards of pharmacopoeias of various countries (such as USP, EP).

- **Application**: ordinary tablets, orally disintegrating tablets.

- **Key parameters**: total impurities <1.5%, single unknown impurities <0.2%.

##### 2. **High-Purity API (High-Purity Grade)**

- **Purity**: ≥99.5%

- **Advantages**:

- Significantly reduce the risk of impurity-related adverse reactions;

- Suitable for sensitive dosage forms (such as oral fast-dissolving films, nano-preparations).

- **Process characteristics**: Multi-step recrystallization combined with HPLC purification to control specific impurities (such as deethyl metabolites).

- **Certification**: Complies with ICH Q3A guidelines.

##### 3. **Customized API (Customized Grade)**

- **Features**: Adjust the particle size (micronized to D90 < 10μm) or crystal form (such as amorphous state) according to the formulation requirements.

- **Advantages**:

- Improve bioavailability and reduce dose-dependent side effects;

- Suitable for compound preparations (such as combined with dapoxetine).

- **Technology**: Spray drying or supercritical fluid technology is used to optimize drug release characteristics.

#### 3. Synthesis process and technological innovation

##### 1. **Classic synthesis route**

- **Starting material**: 4-ethoxybenzoic acid is used as the starting point, and it is prepared through multiple steps such as condensation, cyclization, and sulfonation.

- **Key steps**:

- Microwave-assisted condensation reaction: shorten the reaction time to 1/3 of the traditional method, and increase the yield to 85%;

- Enzyme-catalyzed asymmetric synthesis: reduce chiral impurities, ee value>99%.

##### 2. **Green chemical process**

- **Solvent substitution**: replace DMF with ionic liquid to reduce toxic waste emissions;

- **Continuous flow technology**: realize the continuous production of key intermediates (such as pyrazolopyrimidone) and improve batch consistency.

##### 3. **Process optimization after patent expiration**

- **Patent status**: The original research patent (Bayer) expired in 2018, and generic drug companies adopted non-infringement routes (such as replacement of protective groups).

- **Cost control**: Indian and Chinese companies have reduced the cost of APIs by more than 40% by simplifying the purification steps.

#### 4. Quality standards and regulatory requirements

##### 1. **International Pharmacopoeia Standards**

- **USP**: stipulates related substances, residual solvents (such as methanol <3000ppm), and ignition residues <0.1%;

- **EP**: additional requirements that genotoxic impurities (such as nitrosamines) must not be detected.

##### 2. **Key test items**

- **HPLC method**: Determine the content of the main component and the impurity spectrum;

- **XRD**: Confirm the consistency of the crystal form (avoid the influence of polymorphism on solubility);

- **Particle size analysis**: Laser diffraction method controls the particle size distribution of APIs.

##### 3. **Stability study**

- **Accelerated test**: 6 months at 40℃/75% RH, content decreased by <2%;

- **Long-term storage**: It is recommended to store in a sealed container away from light at 2-8℃, with a shelf life of 36 months.

#### 5. Clinical application and market analysis

##### 1. **Expansion of indications**

- **First-line treatment of ED**: 60% of patients achieved significant improvement at a dose of 10mg;

- **Pulmonary arterial hypertension (PAH)**: Phase II clinical trials showed its potential to dilate pulmonary vasculature, but it has not yet been approved.

##### 2. **Innovation in formulation form**

- **Orodispersible film**: Improve patient compliance, especially for people with dysphagia;

- **Topical gel**: Studies have shown that it can reduce systemic side effects, but bioavailability needs to be optimized.

##### 3. **Global market structure**

- **Major manufacturers**: Sun Pharma of India, Jiangsu Hengrui of China, Bayer of Germany;

- **Market size**: The global ED drug market will be about US$5 billion in 2023, and vardenafil will account for 15%;

- **Growth drivers**: The aging of emerging markets is accelerating, and online diagnosis and treatment drives invisible demand.

#### 6. Safety and risk control

- **Side effects**: Common headaches (9%), flushing (5%), rare blurred vision (<1%);

- **Contraindications**: Combination with nitrates can cause severe hypotension;

- **Quality control risk points**:

- Residual catalysts (such as palladium) in APIs must be controlled to <10ppm;

- Microbial limits must meet the standards for non-sterile APIs (TAMC <1000 CFU/g).

#### 7. Future development trends

1. **Combination therapy development**: Combined with α-receptor blockers to treat ED and BPH;

2. **Bioequivalence optimization**: Improving the efficacy of generic drugs through co-crystal technology;

3. **Digital production**: AI-driven process parameter optimization to achieve "quality by design" (QbD).

#### Conclusion

As the core raw material in the field of ED treatment, the technological progress and quality control of vardenafil API powder directly affect the safety and effectiveness of terminal drugs. With the popularization of green synthesis technology and the rise of personalized medicine, the demand for high-purity and customized APIs will continue to grow. Pharmaceutical companies need to keep up with regulatory trends and combine technological innovation with market demand to gain an advantageous position in the fiercely competitive market.